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Abstract: Background: Frequency doubling technology (FDT) perimetry measures contrast sensitivity. The magnocellu-
lar component of ganglion cells in human retina is isolated as a whole by the FDT stimulus. The aim of this study is to in-
vestigate the role of Humphrey Matrix threshold testing in the detection of early functional retinal impairment in ocular 
hypertensive patients compared to standard automated perimetry (SAP). 
Methodology: Forty hypertensive patients were enrolled in this longitudinal observational clinical study. Functional test-
ing included randomly Humphrey Matrix perimetry and white-on-white Humphrey visual field perimetry. Ibopamine test 
was performed in all forty patients. The cut-off of 3 mmHg was considered positive for this provocative test. 
Results: Out of 40 patients, we included 21 in ibopamine positive group and 19 in ibopamine negative group. These two 
groups are sex- and age-matched. In ibopamine positive group the mean increase in IOP is 4.6 mmHg (ranging from 3 to 
10 mmHg). Statistics showed that correlation between FDT and SAP was statistically significant in ibopamine negative 
group and not statistically significant in ibopamine positive group. Only one patient, coming from IBO + group, converted 
from ocular hypertension to glaucoma. All the other subjects remained stable in both groups without any therapy and vis-
ual field abnormalities. 
Conclusions: FDT showed to be more sensitive and specific than SAP mostly in detection of early visual field impairment 
in ocular hypertensive patients. 
Keywords: Early glaucoma, FDT, ibopamine, ocular hypertension, SAP. 
INTRODUCTION 
  Frequency doubling technology (FDT) perimetry meas-
ures contrast sensitivity. This test is based on an illusion oc-
curring when a sinusoidal grating of low spatial frequency 
undergoes counterphase flickering at a high temporal fre-
quency [1-3]. Recent evidences suggest that the magnocellu-
lar (MGC) pathway in human retina is isolated as a whole by 
the FDT stimulus. The variability of FDT is independent of 
visual field loss [2, 3]. FDT seems to be a useful clinical tool 
to detect mostly early manifest glaucoma. The Humphrey 
Matrix was commercially introduced in 2003 with the fol-
lowing tests: macula 10-2, N-30-F, 24-2 and 30-2 (Fig. 1). 
The Glaucoma Hemifield Test (GHT) is available for the 
FDT 24-2 and 30-2 tests. Recent papers studied the learning 
effect of Matrix FDT and the Authors stressed that it may 
affect only the first test [4] rather than standard automated 
perimetry (SAP). Some years ago, the Ocular Hypertension 
Treatment Study (OHTS) started in the U.S.A. to evaluate 
the safety and efficacy of topical ocular hypotensive medica-
tion in preventing or delaying the onset of visual field loss 
and/or optic nerve damage in subjects affected by ocular hy-
pertension at moderate risk for developing open-angle glau-
coma (OAG) [5]. In U.S.A. it is estimated that 3 to 6 million 
people, including 4% to 7% of the population older than age 
40 years, have elevated intraocular pressure (IOP) without 
detectable glaucomatous damage using current clinical tests  
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[6-13]. Also the pattern electroretinogram was evaluated in 
glaucoma and ocular hypertensive patients [14]. The aim of 
this study is to investigate the role of Humphrey Matrix 
threshold testing in the detection of early functional retinal 
impairment in ocular hypertensive patients compared to 
standard automated perimetry. 
MATERIALS AND METHODS 
  Forty hypertensive subjects (19 male and 21 female), 
mean age 62.92 (SD 12.23) years were enrolled in this longi-
tudinal observational clinical study. All the study partici-
pants gave their informed consent. Inclusion criteria were: 
age > 18 years, clear lens and ocular hypertension (OH). OH 
was defined as: central corneal thickness-adjusted intraocular 
pressure (IOP) > 21 mmHg [15], under diurnal tonometric 
curve, open angle gonioscopy, no visual field damage and no 
systemic and/or topical hypotensive therapy. Exclusion crite-
ria were: spherical refractive error > ±6 diopters; astigma-
tism > ± 3 diopters; active or previous retinal pathologies; 
diagnosis of glaucoma; opacities of dioptric media that could 
bias functional and structural retinal testing; history of ocular 
surgery; any fluorangiographic sign of retinal vasculopathy 
due to diabetes; or other local or systemic disease. All sub-
jects underwent a complete ophthalmological examination 
including: best-corrected visual acuity (BCVA), Goldmann 
applanation tonometry, ibopamine test according to Virno   
et al. [16], slit-lamp examination and indirect ophthal-
moscopy. Functional testing included Humphrey Matrix pe-
rimetry and white-on-white 30-2 SITA standard Humphrey 
visual field perimetry (HFA; Carl Zeiss Meditec, Dublin, FDT vs SAP in Ocular Hypertensive Patients  The Open Ophthalmology Journal, 2009, Volume 3    7 
Ca., U.S.A.). All enrolled subjects performed at least two 
Humphrey visual field perimetry and Matrix visual field tests 
within two weeks using the 30-2 threshold program in order 
to assess the test-retest variability and to rule out a relevant 
learning curve. In all cases the first test was not considered 
[4]. Reliability criteria were defined as less than 33% fixa-
tion errors, false-positives and false-negatives. Pattern stan-
dard deviation (PSD) values were considered for the analy-
sis. Corneal pachymetry from limbus to limbus was per-
formed by the high resolution (HR) Oculus Pentacam. It is a 
rotating Scheimpflug camera which generates images from 
the anterior surface of the cornea to the posterior surface of 
lens. It acquires 50 Scheimpflug images in two seconds. The 
software generates a three-dimensional model of each sur-
face as a basis for corneal topographic and chamber analysis. 
The rotating camera offers anterior segment images in three 
dimensions, creating a movable three-dimensional presenta-
tion of the anterior chamber. The centre of the cornea is 
measured very precisely because of this rotating imaging 
process. 
  The 2% ibopamine test was performed according to 
Virno et al. [16-18]. 2% ibopamine (Trazyl®, Angelini Ac-
raf, Pomezia, Rome, Italy) stimulates -adrenergic receptors 
and D1-dopaminergic receptors in the eye. This pharmacol-
ogical and provocative test is positive if, after 45 minutes 
after the instillation of ibopamine eye drops, IOP increases 
by at least 3 mmHg. All the ibopamine tests were performed 
at the same time, even if the increase of the IOP is absolutely 
independent of the time of day and of the baseline IOP (IOP 
measured before the instillation of ibopamine eye drops). 
This provocative test is widely used in Italy and sometimes 
may be more useful than others such as the water-drinking 
test [19]. All hypertensive patients were divided in two 
groups: ibopamine positive (IBO+) and ibopamine negative 
(IBO-). All patients were classified by Scoring Tool for As-
sessing Risk (S.T.A.R. I and II version) [20]. According to 
the Ocular Hypertension Treatment Study and the European 
Glaucoma Prevention Study (E.G.P.S.) these predictive pa-
rameters were identified as: age, IOP, central corneal thick-
ness (CCT), vertical cup-to-disc ratio, and Humphrey visual 
field pattern standard deviation. This method, in both ver-
sions I and II, gives a percentage of probability of conver-
sion from OH to glaucoma. In this way, it gives some infor-
mation that the clinician may use to make a decision about 
diagnosis and mostly about therapy and follow-up. Statistical 
analysis was performed by descriptive statistics, analysis of 
variance (ANOVA), Bland-Altman method and Spearman 
analysis. 
RESULTS 
  Out of 40 patients, according to the ibopamine test we 
included 13 males and 8 females in IBO + group. In this 
group both eyes were positive to this test. The mean age of 
this group is 60.38 (SD 12.71) years. The remaining 19 sub-
jects (6 males and 13 females) were included in the IBO – 
group. The mean age of the second group is 64.53 (SD 
11.27) years. By chance it happened that the two groups are 
sex- and age-matched (p=0.284). Pachymetrical data are in 
Fig. (2). The mean follow-up in IBO + group is 17.48 
months, in IBO – group is 17.5 months. The follow-up of 
both groups is homogeneous (p=0.997). In ibopamine posi-
tive group the mean IOP increase is 4.6 mmHg (ranging 
from 3 to 10 mmHg). S.T.A.R. I vs S.T.A.R. II measure-
ments in both IBO + and IBO – groups are in Figs. (3-5), ac-
cording to Bland-Altman method. Spearman correlation 
ranking between FDT and SAP visual field tests was statisti-
Fig. (1). FDT technical features. 
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cally significant in IBO – group (p<0.02, Fig. 6) but not sta-
tistically significant in IBO + group (p>0.05, Fig. 7). In the 
whole population studied, only one patient (I.C., male, 45 
years old), belonging to the IBO + group, had a conversion 
from ocular hypertension to open-angle glaucoma during fol-
low-up and started a monotherapy by beta-blocker in both 
eyes. All the other subjects from both groups (IBO + and 
IBO -) remained stable during follow-up without any therapy 
and visual field abnormalities. 
PACHYMETRY 
 
P = 0.914 
Fig. (2). Pachymetrical data (μ) on y-axis and n. of patients on x-axis. 
Fig. (3). STAR I (x-axis) vs STAR II (y-axis) in all patients. 
Fig. (4). STAR I (x-axis) vs STAR II (y-axis) in IBO + group. 
 
Fig. (5). STAR I (x-axis) vs STAR II (y-axis)in IBO – group. 
Fig. (6). SAP (x-axis) vs FDT (y-axis) in IBO – group. 
 
Fig. (7). SAP (x-axis) vs FDT (y-axis) in IBO + group. 
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DISCUSSION 
  We studied a small but homogeneous cohort of hyperten-
sive patients. This cohort of subjects is sex- and age-
matched. No statistical difference was evaluated as for 
pachymetry, S.T.A.R. I and II scores. The HR Pentacam is a 
very useful tool in evaluating pachymetry very precisely ei-
ther in normal population, in OH and glaucoma subjects and 
in refractive surgery patients. Only in ibopamine negative 
group we found a statistical significant correlation between 
FDT and SAP visual field testing. This new pharmacological 
and provocative test (ibopamine test) is very interesting and 
useful in evaluating the possibility to convert from OH to 
glaucoma, also in relatives of glaucoma patients [21]. It is 
very easy to use and allows a very important non-cycloplegic 
mydriasis, useful also in diagnostic testing of outflow im-
pairment. It is safe. In Literature there are no significant 
side-effects described. In OH subjects, such as in normal 
tension glaucoma, its positivity is about 52%. We can specu-
late that, as in Weinreb’s glaucoma continuum [22] and from 
genetical point of view, OH is just a step towards open-angle 
glaucoma and like a “relative” of normal tension glaucoma. 
As we know that Humphrey Matrix threshold testing selec-
tively stimulates the magno-cellular component of ganglion 
cells (3), we underline that this diagnostic tool, associated 
with ibopamine test, can be useful for the identification of 
early visual field impairment in ocular hypertensive subjects, 
suggesting a possible conversion from OH to open-angle 
glaucoma [23]. It may be also useful in the follow-up of 
glaucoma patients even if SAP remains the gold standard of 
our public and private offices. 
REFERENCES 
[1]  Racette L, Medeiros FA, Zangwill LM, et al. Diagnostic accuracy 
of the Matrix 24-2 and original N-30 frequency-doubling technol-
ogy tests compared with standard automated perimetry. Invest 
Opthalmol Vis Sci 2008; 49 (3): 954-60. 
[2]  Parravano M, Oddone F, Mineo D, et al. The role of humphrey 
matrix testing in the early diagnosis of retinopathy in type 1 diabe-
tes. Br J Ophthalmol 2008; 92: 1656-60. 
[3]  White AJR, Sun H, Swanson WH, Lee BB. An examination of 
physiological mechanisms underlying the frequency-doubling illu-
sion. Invest Opthalmol Vis Sci 2002; 43: 3590-9. 
[4]  Centofanti M, Fogagnolo P, Oddone F, et al. Learning effect of 
Humphrey matrix frequency doubling technology perimetry in pa-
tients with ocular hypertension. J Glaucoma 2008; 17 (6): 436-41. 
[5]  Gordon MO, Kass MA. The ocular hypertension treatment study: 
design and baseline description of the participants. Arch Ophthal-
mol 1999; 117 (5): 573-83. 
[6]  Johnson CA, Keltner JL, Cello KE, et al. Baseline visual field 
characteristics in the ocular hypertension treatment study. Oph-
thalmology 2002; 109 (3): 432-7. 
[7]  Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension 
treatment study: baseline factors that predict the onset of primary 
open-angle glaucoma. Arch Ophthalmol 2002; 120 (6): 714-20. 
[8]  Brandt JD, Beiser JA, Gordon MO, et al. Central corneal thickness 
and measured IOP response to topical ocular hypotensive medica-
tion in the ocular hypertension treatment study. Am J Ophthalmol 
2004; 138 (5): 717-32. 
[9]  Medeiros FA, Weinreb RN, Sample PA, et al. Validation of a pre-
dictive model to estimate the risk of conversion from ocular hyper-
tension to glaucoma. Arch Ophthalmol 2005; 123 (10): 1351-60. 
[10]  Levine RA, Demirel S, Fan J, et al. Asymmetries and visual field 
summaries as predictors of glaucoma in the ocular hypertension 
treatment study. Invest Opthalmol Vis Sci 2006; 47 (9): 3896-903. 
[11]  Budenz DL, Anderson DR, Feuer WJ, et al. Detection and prognos-
tic significance of optic disc hemorrhages during the Ocular Hyper-
tension Treatment Study. Ophthalmology 2006; 113 (12): 2137-43. 
[12]  Herman DC, Gordon MO, Beiser JA, et al. Topical ocular hypoten-
sive medication and lens opacification: evidence from the ocular 
hypertension treatment study. Am J Ophthalmol 2006; 142 (5): 
800-10. 
[13]  Bozkurt B, Yilmaz PT, Irkec M. Relationship between humphrey 
30-2 SITA standard test, matrix 30-2 threshold test, and Heidelberg 
retina tomography in ocular hypertensive and glaucoma patients. J 
Glaucoma 2008; 17 (3): 203-10. 
[14]  O’Donaghue E, Arden GB, O’Sullivan F, et al. The pattern elec-
troretinogram in glaucoma and ocular hypertension. Br J Ophthal-
mol 1992, 76, 387-94. 
[15]  Doughty MJ, Zaman ML. Human corneal thickness and its impact 
on intraocular pressure measures: a review and meta-analysis ap-
proach. Surv Ophthalmol 2000; 44: 367-408. 
[16]  Virno M, Pecori-Giraldi J, Taverniti l, et al. Intraocular hyperten-
sive effects of topically administered ibopamine in eyes with hy-
drodynamic disorders: provocative test for glaucoma. Glaucoma 
1990; 12: 88-92. 
[17]  Giuffre’ I. Ibopamine stimulates -adrenergic receptors and D1 
dopaminergic receptors in the eye. Curr Drug Ther 2007; 2(2): 127-
32. 
[18]  Giuffre’ I, Taverniti L, Di Staso S. The effects of 2% ibopamine 
eye drops on the intraocular pressure and pupil motility of patients 
with open-angle glaucoma. Eur J Ophthalmol 2004; 14, 6:508-13. 
[19]  Vetrugno M, Sisto D, Trabucco T, et al. Water-drinking test in pa-
tients with primary open-angle glaucoma while treated with differ-
ent topical medications. J Ocul Pharmacol Ther 2005; 21 (3): 250-
7. 
[20]  Gordon MO, Torri V, Miglior S, et al. Ocular hypertension treat-
ment study group, European glaucoma prevention study group, 
validated prediction model for the development of primary open-
angle glaucoma in individuals with ocular hypertension. Ophthal-
mology 2007; 114(1): 10-9. 
[21]  Pecori-Giraldi J, Damiano A, Gabrielli A, et al. Ocular hyperten-
sion induced by ibopamine early discloses glaucoma suspects 
among relatives of glaucomatous patients. Boll Ocul 2002; 81: 91. 
[22]  Weinreb RN, Friedman DS, Fechtner RD, et al. Perspective. Risk 
assessment in the management of patients with ocular hyperten-
sion. Am J Ophthalmol 2004; 138: 458-67. 
[23]  De Gregorio F, Pecori-Giraldi J, De Stefano C, Virno M. Correla-
tion between ocular hypertension induced by ibopamine and pe-
rimetric defect in primary open-angle glaucoma. Eur J Ophthalmol 
1997; 7: 152-5. 
 
 
Received: January 13, 2009  Revised: February 13, 2009  Accepted: March 2, 2009 
 
© Italo Giuffrè; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: //creativecommons.org/licenses/by- 
nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
 
 